Updated:
Thairm Bio
Thairm Bio is the biotechnology-focused investment office of Thomas Haire, deploying long-duration family and partner capital from Baltimore.
Thairm Bio
Thairm Bio reflects a deliberate convergence of family capital and biotechnology thesis investing, led by Thomas Haire and rooted in Baltimore's growing life-sciences corridor. The entity appears organized to make long-duration commitments to preclinical and clinical-stage drug developers without the standard LP/GP pressure on exit timelines — a structure that mirrors the permanent-capital advantages of a single-family office even if its composition is not publicly detailed. The office targets therapeutics, drug-delivery platforms, and enabling biotech tools. Public records and regulatory filings indicate Thairm Bio has participated in equity rounds for companies such as WindMIL Therapeutics, a Baltimore-born oncology cell-therapy developer, and other regional biotech assets tied to Johns Hopkins and University of Maryland spinouts. Its footprint concentrates on the Mid-Atlantic and broader US life-sciences ecosystems, occasionally extending into syndicates with Pennsylvania- and Boston-based venture investors. Thairm Bio is a lean operation. Unlike multi-billion-dollar family offices that layer real estate, buyout, and venture under one roof, Thairm appears to run a single-sector mandate — biotech — with a handful of professionals. There is no evidence of a parallel philanthropic vehicle or real-asset arm operated under the Thairm name, though the Baltimore/Wayne/Amherst footprint suggests a multi-node personal-or-family infrastructure rather than a large institutional team. Recent operational specifics have not been publicly disclosed. The structural distinction is the office's visible comfort operating where venture capital, grant-funded research, and family-office patience overlap. By staying close to research universities and clinical centers, Thairm Bio positions as a first-in convener for academic founders who need capital without the aggressive milestone pressure of traditional venture funds. That relationship-driven, geography-anchored sourcing model is difficult for generalist investors to replicate.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Baltimore
Corporate office
Baltimore, MD, United States
Principals
Thomas H. Haire
Sector focus
Frequently asked questions
Who runs investment decisions at Thairm Bio?
Thomas H. Haire is the principal associated with Thairm Bio. Public filings and corporate records link him directly to the entity's investment activity. The firm does not publish a broader investment committee or list additional managing directors.
What is Thairm Bio's investment focus?
Thairm Bio concentrates on biotechnology, including therapeutics, drug-development platforms, and enabling life-sciences technologies. Its disclosed investments, such as WindMIL Therapeutics, fall squarely in the clinical-stage oncology space. The firm does not appear to allocate to consumer tech, real estate, or traditional private equity.
How does Thairm Bio structure its investments?
The office primarily participates in direct equity rounds, often at the early or clinical stage, rather than committing to external venture funds as a limited partner. Its investment posture resembles a permanent-capital vehicle linked to a family balance sheet, prioritizing long holding periods over fund-cycle liquidity constraints.
Is Thairm Bio a single-family office or a multi-family office?
The firm's exact structure is not publicly defined, but its operations are consistent with a single-family office or a closely held pooled investment vehicle run by Thomas Haire. No evidence suggests an open architecture accepting external families as clients.
What geographies does Thairm Bio cover?
Thairm Bio's disclosed investments and physical footprint center on the Mid-Atlantic biotech corridor, particularly the Baltimore-Washington region and Pennsylvania. The office has shown willingness to participate in syndicates that extend to Boston and other US life-sciences hubs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: